Navigation Links
Tanespimycin in Medical News

Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma

...rporated (Nasdaq: KOSN ) today announced that the tanespimycin in Myeloma Evaluation or TIME-1 pivotal Phase 3 trial for tanespimycin as a potential treatment for multiple myeloma is o...lment. TIME-1 is a pivotal Phase 3 trial comparing tanespimycin in combination with bortezomib (Velcade(R)) with b...
Tanespimycin in Medical Technology

Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma

Tanespimycin is the First Hsp90 Inhibitor to Enter Registration Trials HAYWARD, Calif., Sept. 6 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) today announced that it has successfully reached a binding agreement with the U.S. Food and Drug Administration (FDA) on th...

Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO

HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented preliminary data from a Phase 2 monotherapy trial showing that tanespimycin demonstrated antitumor activity and tolerability in patients with metastatic melanoma, including one patient with a BRAF mut...

Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial

...ster titled, "Phase 2 trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER...L. "The response data from this Phase 2 trial of tanespimycin plus trastuzumab have grown stronger as more patie...ve been treated, underscoring our observation that tanespimycin is a highly active and tolerable agent in patients...

Kosan Announces Data Presentations at ASCO 2008 Annual Meeting

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash

...alating Phase 1b clinical trial of Hsp90 inhibitor tanespimycin (KOS-953) in combination with bortezomib (Velcade(...n terms of convenience and ease of administration. tanespimycin is clearly an active and manageable agent and is d...ngful antitumor activity and tolerability with the tanespimycin plus bortezomib combination in multiple myeloma ac...

Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial

...rvival. Tanespimycin (KOS-953) is being tested in combination with bortezomib in patients with multiple myeloma in a registration program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with Herceptin, and as monotherapy in metastatic melanoma. Intravenous ...

Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma

... tanespimycin is Industry's First Hsp90 Inhibitor to Enter Regis...IME Registration Program Utilizes New, Proprietary tanespimycin Formulation HAYWARD...olling patients. This marks the opening of Kosan's tanespimycin in Myeloma Evaluation or "TIME" registration progr...

Kosan Announces Data Presentations at Upcoming AACR Annual Meeting

... safety profile and Molecular of tanespimycin Therapeutics 13 (KOS-5: 953) -- ...lved in cancer cell growth and survival. Kosan's proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for mult...
Tanespimycin in Biological Technology

Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs

...porting advancement of its lead clinical programs, tanespimycin in multiple myeloma and in metastatic breast cance...hways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velc...ultiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic ...

Kosan's Board of Directors Appoints Helen S. Kim as Chief Executive Officer

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Announces Senior Management Changes and Clinical Portfolio Priorities

...alue for the company in the near-term. -- The tanespimycin TIME registration program in multiple myeloma, ...myeloma in early 2009. -- Kosan plans to advance tanespimycin in metastatic breast cancer. To lay the groun...Kosan plans to commence enabling studies with tanespimycin as monotherapy and as combination therapy beg...

Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook

... top priorities in 2008 are the advancement of the tanespimycin TIME program in multiple myeloma and the tanespimycin metastatic breast cancer clinical program, and the...hways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with bort...
Other Tags
(Date:8/1/2014)... (HealthDay News) -- Almost 140 people die every ... the United States. But there are several ... Gardner, injury prevention coordinator at Cincinnati Children,s Hospital ... a medical center news release. "As families ... it,s important for parents and children to go ...
(Date:8/1/2014)... 01, 2014 Summer is here, and with ... during the summer, and they can be a pain for ... to help all their customers get rid of ticks and ... 6,000 eggs in the summer, which is why they are ... tall grass and woodland areas and carry a number of ...
(Date:8/1/2014)... bisexual, and transgender individuals who want to conceive a ... their heterosexual and cisgendered peers, such as reduced fertility, ... and legal challenges to become parents. A comprehensive review ... is presented in the article " LGBT Assisted Reproduction: ... LGBT Health , a peer-reviewed journal from ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Growing ... coverage and healthcare reforms are boosting healthcare market ... medicines through discounts and increasing generic consumption is ... approximately 76.7 million in 2013, having grown at ... from 2008. The implementation of the Health Transformation ...
(Date:8/1/2014)... August 01, 2014 On Monday, June ... NextGen User Symposium in San Francisco, CA. Now in ... the JW Marriott Union Square hotel. , “We are ... up to speed with ACA compliance issues,” Quirk Healthcare ... The symposium provides attendees guidance with NextGen implementation and ...
Breaking Medicine News(10 mins):Health News:Expert Offers School Bus Safety Tips 2Health News:Tis the Season for Tick Prevention 2Health News:Advances in assisted reproduction create more options and new legal issues for LGBT couples 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2
(Date:8/1/2014)... at The Scripps Research Institute (TSRI) have identified a ... in brown fat cells. , The study, which ... the Proceedings of the National Academy of Sciences ... fat thermogenesis," which is of great interest to medical ... also protect against diabetes. , "This finding offers new ...
(Date:7/31/2014)... In the United States, natural-gas production from shale ... since 2007. Yet scientists still do not fully ... according to a report in the journal ... As gas extraction continues to vastly outpace scientific ... various organizations and institutions, including Princeton University, concluded ...
(Date:7/31/2014)... Fla. --- By tracing nearly 3,000 genes to ... University of Florida scientists have created an extensive ... use large-scale, next-generation DNA sequencing. , Among ... closely related to small moths than to large ... butterflies evolved. The study also found that some ...
Breaking Biology News(10 mins):Scripps Research Institute scientists find new calorie-burning switch in brown fat 2Scripps Research Institute scientists find new calorie-burning switch in brown fat 3'Fracking' in the dark: Biological fallout of shale-gas production still largely unknown 2'Fracking' in the dark: Biological fallout of shale-gas production still largely unknown 3UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3
Other Contents